Videos

Martin Kulldorff, PhD, explains how an age-based focus for COVID-19 mitigation might better protect both older people and younger people with comorbidities.

Rodney E. Rohde, a clinical laboratory specialist at Texas State University, goes into the competing priorities of college and K-12 school reopening.

Scientists are willing to speak out and have collegial debates – but medical institutions and media have to catch up: fringe voices are often the only ones platformed to discuss important scientific nuances or debates.

In unexposed blood samples, investigators discovered memory helper T cells that recognize cold coronaviruses also recognized SARS-CoV-2, and may help people fight off the virus.

A University of Maryland Professor of Pathology explains that SARS-CoV-2 has unique ways of evading detection.

Pediatricians agree schools are critical for child development and mental health. But their safety from the pandemic cannot be comprised for it.

Citing the rise of the anti-vaccine movement, Peter Hotez, MD, PhD, explains the role scientists can play in building trust and literacy by engaging the public.

Rodney E. Rohde, PhD, a clinical laboratory scientist, helps break down how carefully EUA releases need to be read in order for the public and for scientists from other fields to parse them for useful information.

The ideal time to act on COVID-19 was in January, says public health expert Raj Bhopal.

Armand Balboni, MD, PhD, discusses progress toward FDA authorization and/or approval of favipiravir for COVID-19 as a prophylactic measure.

Two Boston physicians using Interleukin-6 inhibitors report a reduction in intubation and mortality rates.

How can we bridge the divide between the public and public health? Raj Bhopal argues for a strong but supportive pandemic response.

A breakdown of how COVID-19 infection was not managed well in hospitals and ICUs early on.

A Harvard professor and study author discusses new findings showing the heightened risk of healthcare worker infection.

Raj Bhopal, BSc MD, MPH, addresses the nuances of competing ethical priorities societies face amid COVID-19, alongside political battles and terms like “herd immunity.”

RLF-100 is an investigational therapy granted an FDA IND this week and looks to treat moderate and severe cases of COVID-19.

Patrick Soon-Shiong and Dr. Adam Brufsky have an open minded discussion on the dangers and potential lessons of the course Swedish health officials recommended the country take over the SARS-CoV-2 pandemic.

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.

Dr. Patrick Soon-Shiong, CEO of ImmunityBio, initiates a conversation on the nature of the SARS-CoV-2 cytokine storm.

Adam Brufsky, MD, explains the insights years of research into SARS-CoV-1 may hold for SARS-CoV-2.

A New York City cardiologist talks about the presentation of patients with severe COVID-19 who experienced this condition.

Medha Munshi, MD, discusses the specific challenges of the quarantine and how she was able to help her patients with diabetes comply with their care.

What role does new research play in combating public vaccination concerns?

Peter Hotez, MD, PhD, recently authored a paper proposing a federally directed but state-adaptive reopening that aims for acceptable national suppression by October 1.

A discussion on the process by which the FDA regulates vaccine candidates at a time when COVID-19 candidates are progressing.

Why reducing pandemic research and response to yes-or-no outcomes is harming public health.

Dr. Adam Brufsky, an oncologist, compares viral and cancer immunity. Dr. Patrick Soon-Shiong connects the relation to COVID-19 vaccine research.

What should be anticipated in effectiveness and implication for the leading candidates.